Peripheral blood lymphocyte subset levels differ in patients with hepatocellular carcinoma.
We investigated the levels of target lymphocyte subsets in peripheral blood lymphocyte samples from patients with hepatocellular carcinoma (HCC). A total of 715 high-risk patients with primary HCC were recruited in Guangxi, China as the case group. The control group included 100 patients who received health examinations at the same hospital during the same period. Fasting elbow venous blood (10 mL) was collected from each participant, and flow cytometry was used to detect the levels of NK cells and CD3+, CD4+ and CD19+ T cells in peripheral blood samples. All included patients with prmary HCC were treated by surgical resection, and followed up for one year. The levels of CD19+ and NK cells were lower in cases than in controls (both P < 0.05). In addition, the level of CD8+ cells was greater in the case group than in the control group (P < 0.05). In the high-HCC-risk population, CD8+, CD19+ and NK cell levels all differed between male and female patients, patients in TNM stages I-II and stages III-IV, patients with and without extrahepatic metastasis, and patients with and without HBV infection (all P < 0.05). After follow-up, detected recurrence and survival rate was 33.71% and 83.64%, respectively. CD8+ levels was reduced following surgical resection, whereas the levels of CD19+ and NK cells were increased (all P < 0.05). In conclusion, altered levels of CD8+, CD19+ and NK cell levels may be used as reference values for monitoring immune function in certain populations with high HCC risk, and as potential evidence for the clinical diagnosis and treatment of HCC.
Department of Medical Research, The Affiliated Tumor Hospital of Guangxi Medical University, 530021 Nanning, Guangxi, P.R. China.
Hai-Zhou
HZ
Liu
Department of Medical Research, The Affiliated Tumor Hospital of Guangxi Medical University, 530021 Nanning, Guangxi, P.R. China.
Wei
W
Deng
Department of Medical Research, The Affiliated Tumor Hospital of Guangxi Medical University, 530021 Nanning, Guangxi, P.R. China.
Ji-Lin
JL
Li
Department of Medical Research, The Affiliated Tumor Hospital of Guangxi Medical University, 530021 Nanning, Guangxi, P.R. China.
Ya-Mei
YM
Tang
Department of Medical Research, The Affiliated Tumor Hospital of Guangxi Medical University, 530021 Nanning, Guangxi, P.R. China.
Li-Tu
LT
Zhang
Department of Medical Research, The Affiliated Tumor Hospital of Guangxi Medical University, 530021 Nanning, Guangxi, P.R. China.
Ying
Y
Cui
Department of Medical Research, The Affiliated Tumor Hospital of Guangxi Medical University, 530021 Nanning, Guangxi, P.R. China.
Xin-Qiang
XQ
Liang
D000328:Adult; D015703:Antigens, CD / Q000378:metabolism; D006528:Carcinoma, Hepatocellular / Q000097:blood* / Q000175:diagnosis / Q000401:mortality; D005260:Female; D005434:Flow Cytometry; D006801:Humans; D016130:Immunophenotyping; D008113:Liver Neoplasms / Q000097:blood* / Q000175:diagnosis / Q000401:mortality; D018655:Lymphocyte Count; D016131:Lymphocyte Subsets / Q000378:metabolism; D008297:Male; D008875:Middle Aged; D011379:Prognosis
D015703:Antigens, CD
CD19+; CD3+; CD4+; NK cells; hepatocellular carcinoma